BMS NOX to partner on pilot study, page-4

vrs

BMS Partnering

From this source:

Partnering plays a strategic role in executing our R&D strategy, evolving our portfolio and growth. Our goal in partnering is to discover, develop and deliver transformational medicines to patients by bringing innovative science, research and technology together with our capabilities and expertise.

And:

External innovation and partnering are critical drivers of out strategy and have brought significant commercial success and pipeline growth. 60% of our current development pipeline is externally sourced and 12 of our 20 blockbuster drugs are derived from collaborations.

So the interest from BMS is based on fact. It appears that they would be open to the notion that Veyonda could indeed be a transformational medicine.